Risperidone tablets

Risperidone is a selective monoamine antagonist with high affinity for 5HT2 receptors, D2 receptors, α1 and α2 receptors, and H1 receptors. It also has antagonistic effects on other receptors, but they are weaker. It has low to moderate affinity for 5HT1C, 5HT1D, and 5HT1A, weak affinity for D1 and haloperidol-sensitive σ receptors, and no affinity for M receptors or β1 and β2 receptors. Like other drugs for the treatment of schizophrenia, the mechanism of risperidone in the treatment of schizophrenia is still unclear. It is believed that its therapeutic effect is the result of the combined effect of antagonism of D2 receptors and 5HT2 receptors. Antagonism of receptors other than D2 and 5HT2 may be related to other effects of risperidone.

3-[2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-α]pyrimidin-4-one

This product is a film-coated tablet, which appears white or off-white after removing the coating.

It is used to treat acute and chronic schizophrenia and other various psychotic states with obvious positive symptoms (such as hallucinations, delusions, disordered thinking, hostility, suspicion) and obvious negative symptoms (such as slow response, emotional indifference and social indifference, few words). It can also alleviate the emotional symptoms related to schizophrenia (such as depression, guilt, anxiety). For patients who are effectively treated in the acute phase, Risperdal can continue to exert its clinical efficacy in the maintenance phase of treatment.

Adults: once or twice a day. The initial dose is 1 mg, and the dose is gradually increased to 2-4 mg per day within a week or so, and gradually increased to 4-6 mg per day within the second week. After that, this dose can be maintained unchanged, or further adjusted according to personal circumstances. In general, the optimal dose is 2-6 mg per day. The daily dose generally does not exceed 10 mg.

1. Common adverse reactions associated with taking this product are: insomnia, anxiety, agitation, headache, dizziness, and dry mouth. 2. Less common adverse reactions include: drowsiness, fatigue, decreased concentration, constipation, indigestion, nausea, vomiting, abdominal pain, blurred vision, abnormal penile erection, erectile dysfunction, weak ejaculation, sexual apathy, urinary incontinence, rhinitis, rash, and other allergic reactions. 3. May cause extrapyramidal symptoms such as: muscle tension, tremor, rigidity, drooling, bradykinesia, akathisia, and acute dystonia. This can be eliminated by reducing the dose or administering anti-Parkinson's drugs. 4. Occasionally, symptoms of (postural) hypotension, (reflex) tachycardia, or hypertension may occur.

Patients with known hypersensitivity to this product are contraindicated.

Precautions for children: There is currently insufficient clinical experience for children under 15 years old. Precautions for pregnancy and lactation: It is not clear whether this product is safe for pregnant women to take it. Animal experiments have shown that risperidone has no direct toxicity to reproduction and no teratogenic effects. Nevertheless, pregnant women should not take this product unless the benefits clearly outweigh the possible risks. It is not clear whether this product is excreted through human breast milk. Animal experiments have shown that risperidone and 9-hydroxyrisperidone are excreted through animal milk. Therefore, women taking this product should not breastfeed. Precautions for the elderly: The recommended starting dose is 0.5 mg or less per day. According to individual needs, the dose is gradually increased to 1-2 mg twice a day, and the dose adjustment interval should be no less than 1 week. The dose increase or decrease range is 0.5 mg twice a day. Before gaining more experience, the elderly should be cautious in the process of increasing the dose.

1 This product can antagonize the effects of levodopa and other dopamine agonists. 2 Carbamazepine and other liver enzyme inducers will reduce the plasma concentration of the active ingredient of this product. Once carbamazepine or other liver enzyme inducers are stopped, the dosage of this product should be re-determined and reduced if necessary. 3 Phenothiazines, tricyclic antidepressants and some beta-blockers will increase the blood concentration of this product, but will not increase the blood concentration of the antipsychotic active ingredient. 4 When taken together with other highly protein-bound drugs, there is no clinically significant mutual replacement of plasma proteins.

Store in sealed container at 15-30°C.

1 mg

36 months

Zhe JIANG HUA HAI Pharmaceutical Co., Ltd.

• Founded in:

  2001-02-28

• Address:

  Xunqiao, Linhai City, Zhejiang Province

• Tax NO.:

  91330000147968817N

• Registered Funds:

  1.491754938 yuan

• Website:

  Log in to view

• Email:

  Log in to view